EGFR-TKI治疗EGFR敏感突变的晚期NSCLC一线与二线疗效对比的研究进展
| 作者: |
1应梦洁,
1孙建立
1 上海中医药大学附属龙华医院肿瘤六科，上海 200232 |
| 通讯: |
孙建立
Email: 1721679167@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.06.022 |
| 基金: | 国家自然科学基金委员会资助项目, 81573890 上海市进一步加快中医药事业发展三年行动计划, CCCX-3-3001 国家中医药管理局国家中医临床研究基地业务建设科研专项课题, JDZX2015069 |
摘要
本文对近年来关于表皮生长因子络氨酸激酶抑制剂(EGFR-TKI)的多项研究进行分析：EGFR-TKI与传统化疗相比，无论一线还是二线治疗表皮生长因子(EGFR)突变的非小细胞肺癌(non-small cell lung cancer，NSCLC)患者均能够提高客观缓解率(objective response rate，ORR)，延长无进展生存期(progression free survival，PFS)，改善生活质量；应尽早明确患者基因突变状态，二线治疗进行基因检测也是十分必要的；对于EGFR敏感突变的患者，有研究显示EGFR-TKI一线治疗与二线治疗相比，能提高有效率及疾病控制率，但并未见PFS及总生存期(overall survival，OS)的延长。
关键词：
非小细胞肺癌
表皮生长因子络氨酸激酶抑制剂
一线治疗
二线治疗
Progress in patients with EGFR sensitive mutation advanced non-small cell lung cancer: comparison of therapeutic efficacy of EGFR-TKI as first- or second-line therapy
CorrespondingAuthor: SUN Jianli Email: 1721679167@qq.com
DOI: 10.3978/j.issn.2095-6959.2016.06.022
Abstract
The article discusses a number of studies on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in recent years: advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation patients treated with EGFR-TKI compared with that of the patients treated with chemotherapy, the objective response rate (ORR) and progression-free survival (PFS) significantly increased, the quality of life improved, both in first- or second-line therapy; gene mutation status should be made clear as early as possible, even for chemotherapy-treated patients, genetic testing is also very necessary; There are studies show that EGFR-TKI treat patients with EGFR mutations, the response rate and disease control rate in chemonaive patients are higher than those in chemotherapy-treated patients, however, there is no difference in PFS and OS.